SLEEMAN; Mark W.
Patent Applications and Registrations
Patent applications and USPTO patent grants for SLEEMAN; Mark W..The latest application filed is for "anti-angptl3 antibodies and uses thereof".
Company Profile
5.19.27
- SLEEMAN; Mark W. - Richmond AU
- SLEEMAN; Mark W. - Victoria AU
- Sleeman; Mark W. - Melbourne AU
- Sleeman; Mark W. - Mahopac NY
Patent Activity
| Patent | Date |
|---|---|
| Anti-angptl3 Antibodies And Uses Thereof App 20220153825 - SLEEMAN; Mark W. ; et al. | 2022-05-19 |
| Anti-pcsk9 Antibodies App 20210253735 - SLEEMAN; Mark W. ; et al. | 2021-08-19 |
| Anti-PCSK9 antibodies Grant 10,941,210 - Sleeman , et al. March 9, 2 | 2021-03-09 |
| Anti-angptl3 Antibodies And Uses Thereof App 20190315851 - SLEEMAN; Mark W. ; et al. | 2019-10-17 |
| Anti-ANGPTL3 antibodies and uses thereof Grant 10,358,487 - Sleeman , et al. July 23, 2 | 2019-07-23 |
| Anti-pcsk9 Antibodies App 20190135941 - Sleeman; Mark W. ; et al. | 2019-05-09 |
| Anti-angptl3 Antibodies And Uses Thereof App 20190092845 - SLEEMAN; MARK W. ; et al. | 2019-03-28 |
| Anti-PCSK9 antibodies Grant 10,023,654 - Sleeman , et al. July 17, 2 | 2018-07-17 |
| Anti-ANGPTL3 antibodies and uses thereof Grant 9,951,127 - Sleeman , et al. April 24, 2 | 2018-04-24 |
| Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9 App 20170296657 - Sleeman; Mark W. ; et al. | 2017-10-19 |
| Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9 Grant 9,724,411 - Sleeman , et al. August 8, 2 | 2017-08-08 |
| ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS App 20170096496 - SLEEMAN; Mark W. ; et al. | 2017-04-06 |
| Therapeutic uses of anti-PCSK9 antibodies Grant 9,550,837 - Sleeman , et al. January 24, 2 | 2017-01-24 |
| ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS App 20150284474 - SLEEMAN; Mark W. ; et al. | 2015-10-08 |
| Human antibodies to human angiopoietin-like protein 4 Grant 9,120,851 - Sleeman , et al. September 1, 2 | 2015-09-01 |
| Anti-ANGPTL3 Antibodies and Uses Thereof App 20150197564 - Sleeman; Mark W. ; et al. | 2015-07-16 |
| Anti-ANGPTL3 antibodies and uses thereof Grant 9,018,356 - Sleeman , et al. April 28, 2 | 2015-04-28 |
| Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9 App 20140099312 - Sleeman; Mark W. ; et al. | 2014-04-10 |
| Human Antibodies To Human Angiopoietin-like Protein 4 App 20130266574 - SLEEMAN; Mark W. ; et al. | 2013-10-10 |
| High affinity human antibodies to PCSK9 Grant 8,501,184 - Sleeman , et al. August 6, 2 | 2013-08-06 |
| Anti-ANGPTL3 Antibodies and Uses Thereof App 20130171149 - Sleeman; Mark W. ; et al. | 2013-07-04 |
| ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS App 20130085266 - SLEEMAN; Mark W. ; et al. | 2013-04-04 |
| Methods For Treating Hypercholesterolemia Using Antibodies To Pcsk9 App 20130064834 - SLEEMAN; Mark W. ; et al. | 2013-03-14 |
| Methods for treating hypercholesterolemia using antibodies to PCSK9 Grant 8,357,371 - Sleeman , et al. January 22, 2 | 2013-01-22 |
| Human antibodies to human angiopoietin-like protein 4 Grant 8,354,103 - Sleeman , et al. January 15, 2 | 2013-01-15 |
| High affinity human antibodies to PCSK9 Grant 8,062,640 - Sleeman , et al. November 22, 2 | 2011-11-22 |
| Methods for Treating Hypercholesterolemia Using Antibodies to PCSK9 App 20110256148 - SLEEMAN; MARK W. ; et al. | 2011-10-20 |
| Human Antibodies To Human Angiopoietin-like Protein 4 App 20110159015 - SLEEMAN; Mark W. ; et al. | 2011-06-30 |
| High Affinity Human Antibodies To Pcsk9 App 20110065902 - Sleeman; Mark W. ; et al. | 2011-03-17 |
| High Affinity Human Antibodies to PCSK9 App 20100166768 - Sleeman; Mark W. ; et al. | 2010-07-01 |
| Methods of treating type I diabetes by blocking VEGF-mediated activity Grant 7,378,095 - Cao , et al. May 27, 2 | 2008-05-27 |
| Methods of treating diabetes by blocking VEGF-mediated activity Grant 7,052,691 - Sleeman , et al. May 30, 2 | 2006-05-30 |
| Methods of treating obesity with combination therapeutics App 20060058224 - Yancopoulos; George D. ; et al. | 2006-03-16 |
| Methods of treating type I diabetes by blocking VEGF-mediated activity App 20060024309 - Cao; Jingtai ; et al. | 2006-02-02 |
| OGH fusion polypeptides and therapeutic uses thereof App 20050250185 - Murphy, Andrew J. ; et al. | 2005-11-10 |
| Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones App 20050096264 - MacDonald, Lynn ; et al. | 2005-05-05 |
| Methods of treating diabetes by blocking VEGF-mediated activity App 20040213787 - Sleeman, Mark W. ; et al. | 2004-10-28 |
| Transgenic SHIP2 animals and in vivo screening methods App 20040205831 - Sleeman, Mark W. ; et al. | 2004-10-14 |
| Method of treating liver steatosis in a mammal App 20040142868 - Sleeman, Mark W. | 2004-07-22 |
| Therapeutic method for combined use of modified CNTF and thiadolidinedione App 20040033954 - Sleeman, Mark W. | 2004-02-19 |
| Modified ciliary neurotrophic factor, method of making and methods of use thereof Grant 6,680,291 - Wiegand , et al. January 20, 2 | 2004-01-20 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 